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Adipose tissue dysfunction as a 
central mechanism leading to 
dysmetabolic obesity triggered by 
chronic exposure to p,p’-DDE
Diogo Pestana  1,2,3, Diana Teixeira1,2,3, Manuela Meireles3, Cláudia Marques1,2,3, Sónia 
Norberto3, Carla Sá3, Virgínia C. Fernandes4, Luísa Correia-Sá4, Ana Faria1,2,3,5, Luísa 
Guardão6, João T. Guimarães  3,7, Wendy N. Cooper8, Ionel Sandovici8, Valentina F. 
Domingues  4, Cristina Delerue-Matos4, Rosário Monteiro3,9, Miguel Constância8 & Conceição 
Calhau1,2,3
Endocrine-disrupting chemicals such as p,p’-dichlorodiphenyldichloroethylene (p,p’-DDE), are 
bioaccumulated in the adipose tissue (AT) and have been implicated in the obesity and diabetes 
epidemic. Thus, it is hypothesized that p,p’-DDE exposure could aggravate the harm of an obesogenic 
context. We explored the effects of 12 weeks exposure in male Wistar rats’ metabolism and AT biology, 
assessing a range of metabolic, biochemical and histological parameters. p,p’-DDE -treatment 
exacerbated several of the metabolic syndrome-accompanying features induced by high-fat diet (HF), 
such as dyslipidaemia, glucose intolerance and hypertension. A transcriptome analysis comparing 
mesenteric visceral AT (vAT) of HF and HF/DDE groups revealed a decrease in expression of nervous 
system and tissue development-related genes, with special relevance for the neuropeptide galanin that 
also revealed DNA methylation changes at its promoter region. Additionally, we observed an increase in 
transcription of dipeptidylpeptidase 4, as well as a plasmatic increase of the pro-inflammatory cytokine 
IL-1β. Our results suggest that p,p’-DDE impairs vAT normal function and effectively decreases the 
dynamic response to energy surplus. We conclude that p,p’-DDE does not merely accumulate in fat, 
but may contribute significantly to the development of metabolic dysfunction and inflammation. 
Our findings reinforce their recognition as metabolism disrupting chemicals, even in non-obesogenic 
contexts.
A combination of complex events are contributing to the current obesity epidemic and ultimately to the metabolic 
syndrome (MetS), a serious worldwide health threat1. Metabolic disorders such as cardiovascular diseases (CVD) 
and type 2 diabetes mellitus (T2D) result from alterations of metabolic pathways in several organs. They are the 
result of the co-occurrence of obesity (particularly central obesity), dyslipidaemia, hyperglycaemia and hyper-
tension2. Amongst obese individuals, variable prevalence of cardiometabolic complications is often observed, 
with metabolically healthy subjects accounting for 10–25%3. A central role in unhealthy obesity, also known 
as dysmetabolic obesity, is attributed to visceral adipose tissue (vAT) dysfunction and inflammation, affecting 
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the dialog with other central (brain) and peripheral organs (liver, gut, muscle), but causal factors are still largely 
unknown3, 4.
The rate at which the prevalence of these conditions are increasing suggests that environmental and behav-
ioural influences are “fuelling” the epidemic5, 6. Concerns have focused on the hypothesis that exposure to envi-
ronmental endocrine-disrupting chemicals (EDCs) may be involved in the rise of obesity and MetS epidemic 
observed worldwide in the last 40 years. In particular, the man-made lipophilic persistent organic pollutants 
(POPs) with hormone-like activity (endocrine disruptors) can lead to an environmental disruption of metabolism 
and putative diabetogenic effect5, 7–11. POPs are bioaccumulated and biomagnified in the food chain and can be 
found in the adipose tissue (AT) of virtually all human populations12, functioning not only as a reservoir and a 
source of chronic internal exposure, but also as a possible tissue target of their disruptive effects13, 14. Due to their 
lipophilic nature, food consumption represents the main pathway for exposure to these contaminants, namely 
through ingestion of fat-containing food such as dairy products, meat and fish8, 15–17.
Recently, a series of studies concerning the burden of disease and cost analysis of exposure to EDCs revealed 
a likely substantial contribution to disease and dysfunction across the life course with elevated annual costs, both 
in the European Union and USA, emphasizing the need for evaluation of effects, better monitoring and active 
prevention18–20. Supporting these warnings are, among others, several epidemiological and in vivo studies that 
reported the positive correlation of EDCs concentrations, both in AT and plasma, with the prevalence of obesity, 
MetS, insulin resistance, hypertension and CVD21–23, as well as adipocyte dysfunction24.
Studies such as those developed by Ruzzin et al. where dietary supplementation with salmon oil contaminated 
with a mixture of POPs in conjunction with high-fat (HF) diet feeding promoted the development of obesity 
and T2D in a rodent model25, 26, led to the proposition of a broader metabolism disrupting chemical hypothesis 
where ECDs act as metabolic disruptors that increase the susceptibility to metabolic diseases7, 10, 27, 28. A recent 
publication reviewed the putative mechanisms of metabolic disruption28, highlighting the effects on adipogen-
esis and adipokine production29, 30, neuroendocrine control of feeding and metabolism31, 32, energy homeostasis 
and T2D trough alteration of insulin action, glucose disposal and beta cell survival and function33, as well as 
hepatic steatosis34, and hyperlipidemia35. Involved molecular mechanism encompass the alteration of hormonal 
and homeostatic systems related to sex hormones (e.g. estrogens and androgens, thyroid function and corticoster-
oids) acting through nuclear receptors, nonnuclear steroid hormone receptors, nonsteroid receptors (for example, 
neurotransmitter receptors), orphan receptors (such as aryl hydrocarbon receptor, AhR), endoplasmic reticulum 
and oxidative stress, inflammatory disruption and epigenetic changes7, 28.
In a recent paper, Gauthier et al.36 showed that the metabolically dysfunctional obese phenotype was associated 
with higher plasma POP levels. Results from our group in obese individuals revealed that POP levels especially 
in vAT, the main reservoir, were higher in subjects with evidence of metabolic abnormalities27, 37, thus comple-
menting and strengthening the Gauthier study. In this context, the mechanisms by which POPs exert their effects 
could involve various pathways including dysregulation of hormonal systems, nuclear receptors and epigenetic 
processes, in addition to possible action on neurotransmitter receptors and systems38. Altogether, these mecha-
nisms could ultimately interfere with AT remodeling and function with local and systemic consequences21, 24, 39. 
Hence, POPs stored in AT may be a key component in the pathogenesis of MetS, in synergy with lifestyle factors, 
to promote obesity and its associated complications, namely T2D21, 24, 40.
One of these synthetic organic chemicals is the pesticide p,p’-dichlorodiphenyldichloroethylene (p,p’-DDE), 
which has been associated with an increased prevalence of obesity and T2D in several epidemiological studies41, 42. 
However the causal relationship and specific mechanisms of action are still under discussion. This study 
was designed to evaluate if exposure of rats to sustained low levels of p,p’-DDE (2.5 times less than 
lowest-observed-adverse-effect level), either in presence or absence of a HF diet, could contribute to the appear-
ance or aggravation of metabolic disorders and possible functioning as an environmental modifier between 
obesity subphenotypes3. For this purpose, the metabolic characterization of these rats was accompanied by a 
comprehensive and integrative evaluation of vAT histology, transcriptome and DNA methylation changes in key 
differentially expressed genes.
Results
Weight measurements and body composition. HF fed rats had a significantly accelerated growth dur-
ing the treatment (Fig. 1), evident in body weight evolution, weight gain per animal and energy intake (kcal/day/
animal). Exposure to p,p’-DDE did not alter body weight profile in any of the diets. At the end of the treatment, 
both groups that ingested HF had significantly higher fat mass (bioelectrical impedance evaluation, p < 0.0001) 
and an effect in heart and pancreas (p = 0.014 and p = 0.012), respectively increasing and decreasing their weights.
AT - distribution, lipolysis and p,p’-DDE accumulation. HF diet, independently of exposure to 
p,p’-DDE, had a significant effect on AT weight increase (Fig. 2A). In contrast, vAT mature adipocytes basal lipol-
ysis (Fig. 2B) was decreased when p,p’-DDE exposed and non-exposed animals were fed with HF diet, translated 
by a smaller glycerol and non-esterified fatty acids (NEFAs) release (p < 0.0001 and p = 0.0022). Nevertheless, 
p,p’-DDE exposure increased vAT lipolysis (glycerol, p = 0.0255), an effect more pronounced in St/DDE rats 
without the overwhelming effect of HF diet. p,p’-DDE was only present in AT of exposed rats (data not shown) 
and its concentration was higher in St/DDE compared to HF/DDE rats in both mesenteric and subcutaneous AT 
depots (Fig. 2CI). However, no difference between exposed groups was observed in p,p’-DDE burden, calculated 
after normalization for AT weight (Fig. 2CII).
Evaluation of MetS features. An oral glucose tolerance test (OGTT) was performed after 7 weeks of 
treatment (Fig. 3A) to evaluate the effects of p,p’-DDE exposure in glycaemic response in both diets. The animals 
from both groups fed with HF diet exhibited impaired glucose tolerance, being more pronounced in HF/DDE 
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group (Fig. 3AI). Unlike standard diet-fed groups, glycaemia did not return to baseline in HF/DDE and HF 
after 120 min of glucose administration. Total area under the curve (AUC) of the glycaemic response was calcu-
lated for each experimental group (Fig. 3AIII). HF diet increased the AUC independently of p,p’-DDE exposure 
(p = 0.0063), but in addition to a later and higher glucose peak in the OGTT, the effect of HF/DDE treatment 
was also reflected by a higher AUC comparing to St (p < 0.05, Tukey’s post-hoc test). In turn, p,p’-DDE exposure 
had a significant increasing effect on fasting glucose independently of the diet (p = 0.0033, Fig. 3AII). Fasting 
insulin levels (Fig. 3AIV) at the end of the treatment were tendentiously higher in HF diet groups, a tendency 
more pronounced in HF/DDE animals, which is in accordance to the results obtained for this group in OGTT. 
Correspondingly, homeostasis model assessment (HOMA) of insulin resistance indicated the same pattern 
(Fig. 3AV).
HF/DDE rats were hypertensive since week 4, with systolic blood pressure (SBP) >140 mmHg (Fig. 3B). 
Overall, p,p’-DDE exposure was responsible for SBP variation, demonstrated by higher SBP in St/DDE and HF/
DDE at 10 weeks (p = 0.0098). At the end of treatment (Fig. 3C), we observed that high-density lipoprotein 
(HDL) cholesterol levels were higher in animals fed with HF diet (p = 0.0041), however the increase in HDL levels 
caused by HF/DDE treatment was more pronounced comparing to St groups (p < 0.05, Tukey’s post-hoc test). 
The same pattern was observed for cholesterol. Regarding NEFAs, the HF diet effect was opposite to HDL, with 
lower levels in HF-treated animals (p = 0.0485).
Biochemical parameters and circulating cytokine profiles. Plasma and urine biochemical parameters 
can be found as Supplementary Table S1. A significant interaction between HF diet and p,p’-DDE exposure was 
observed, resulting in the increase of plasma uric acid and lactate levels only in HF/DDE animals (interaction; 
Figure 1. Weight measurements and body composition: (A) body weight evolution throughout the 12 weeks 
of treatment; (B) body weight gain per animal; (C) energy intake (kcal) per day/animal calculated trough food 
intake assessment; (D) fat mass evaluated by bioelectrical impedance at 12 weeks; (E) organ weights at 12 weeks. 
Values are represented as mean ± SEM. Statistical analysis with (A) two-way repeated-measures ANOVA; 
(B,C,D and F) two-way ANOVA (main effects: diet, p,p’-DDE exposure and their interaction; p < 0.05), 
followed by Tukey’s multiple comparison post-hoc test: *p < 0.05 vs St and St/DDE. St, standard diet; HF, high 
fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene.
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p = 0.0015 and p = 0.0114). The same pattern was observed in some of the cellular damage plasma marker levels, 
with a significant increase of amylase, aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, 
AST and creatine kinase (CK) only in HF/DDE animals (interaction; p = 0.0156, p = 0.0376, p = 0.0484 and 
p = 0.0241, respectively).
Figure 2. Adipose tissue (AT) depot weight (A), lipolysis in isolated mature adipocytes (B) and p,p’-DDE levels 
in AT (concentration, CI; burden, CII), after 12 weeks. Values are represented as mean ± SEM. Statistical analysis 
with (A,B) two-way ANOVA (main effects: diet, p,p’-DDE exposure and their interaction; p < 0.05), followed by 
Tukey’s multiple comparison post-hoc test: *p < 0.05 vs St and/or St/DDE; (C) unpaired t test when comparing 
between treatment groups (St/DDE and HF/DDE) and paired t test when comparing between different ATs from 
the same treatment group: *p < 0.05. St, standard diet; HF, high fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroet
hylene; vAT, visceral adipose tissue; scAT, subcutaneous adipose tissue; NEFAs, non-esterified fatty acids.
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Urinary glucose levels were higher in HF diet-fed groups (p = 0.0301), but more prominent in HF/DDE ani-
mals. In the same way, microalbuminuria, which presence in urine is in itself alarming, was affected both by diet 
and p,p’-DDE exposure (p = 0.0473 and p = 0.0332, respectively), with a significant increase in HF/DDE animals 
compared to their St and HF counterparts (p < 0.05, Tukey’s post-hoc test).
Circulating cytokines levels at 12 weeks (Fig. 4), showed a significant increase in leptin and leptin/adiponec-
tin ratio by HF diet (p < 0.0001 and p = 0.0004). No significant differences were observed in TNF-α and MCP-1 
Figure 3. Metabolic syndrome features. (A) oral glucose tolerance test (OGTT) at the 7th week: (I) blood 
glucose variation, (II) fasting glucose, (III) blood glucose area under the curve (AUC) and (IV) fasting insulin 
levels and (V) homeostasis model assessment (HOMA) of insulin resistance after 12 weeks; (B) systolic blood 
pressure at 4, 7 and 10 weeks; and (C) plasma lipid profile at the end of treatment: total cholesterol, triglycerides, 
high-density lipoprotein (HDL) cholesterol, cholesterol low-density lipoprotein (LDL) and non-esterified fatty 
acids (NEFAs). Statistical analysis with two-way ANOVA (main effects: diet, p,p’-DDE exposure and their 
interaction; p < 0.05), followed by Tukeys’s multiple comparison post-hoc test. (A) #p < 0.05 HF/DDE vs St and 
*p < 0.05 HF vs St; (B,C) *p < 0.05 between selected groups. St, standard diet; HF, high fat diet; p,p’-DDE, p,p’-
dichlorodiphenyldichloroethylene.
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levels. In contrast, IL-1β levels increased both by HF (p = 0.0028) and p,p’-DDE exposure (p = 0.0034), but with 
a significant increase in HF/DDE-treated rats when compared with all other groups (p < 0.05, Tukey’s). We 
observed an opposite effect for anti-inflammatory cytokines IL-10 and TGF-β1.
Figure 4. Effect of 12 weeks of treatment on circulating cytokine profile: leptin, adiponectin and their ratio; 
pro-inflammatory cytokines interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α) and monocyte 
chemotactic protein 1 (MCP-1); anti-inflammatory cytokines interleukin-10 (IL-10) and transforming growth 
factor-beta 1 (TGF-β1). Statistical analysis with two-way ANOVA (main effects: diet, p,p’-DDE exposure and 
their interaction; p < 0.05), followed by Tukey’s multiple comparison post-hoc test: *p < 0.05 vs St; #p < 0.05 vs 
HF/DDE. St, standard diet; HF, high fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene.
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Mesenteric vAT morphology. Adipocyte area (Fig. 5) was higher in HF diet groups (p < 0.0001). HF/DDE 
rats (vs HF) had an increase in % smaller/medium (<4000 µm2) and a decrease of bigger (>6000 µm2) adipocytes. 
We observed increased proliferation in St/DDE and HF rats, but the interaction between HF diet and p,p’-DDE 
exposure led to a significant decrease (p = 0.0038). Moreover, HF diet contributed for increased percentage of 
apoptotic cells, independently of exposure to p,p’-DDE (p = 0.0356).
Comparison of global gene expression between HF and HF/DDE rats. Gene expression microar-
rays in mesenteric vAT from HF and HF/DDE rats showed that 320 genes were up-regulated and 311 were 
down-regulated (at least 1.25-fold change). Detailed data concerning up- and down-regulated genes are shown 
in Supplementary Table S2. The largest changes induced by HF/DDE were seen in down-regulated genes, such 
as galanin (Gal; −4.92-fold), cholinergic receptor nicotinic alpha 3 (Chrna3; −3.20-fold), somatostatin (Sst; 
−2.88-fold), neuromedin U (Nmu; −2.75-fold) or neuropeptide Y (Npy; −1.78-fold). Expression of genes such as 
dipeptidylpeptidase 4 (Dpp4; 2.36-fold) and ISL LIM homeobox 1 (Isl1; 1.77-fold) were up-regulated.
The differentially transcribed genes, mainly the down-regulated genes, were associated with several biolog-
ical functions and pathways (Table 1). Cell-to-cell signalling and interaction, nervous system development and 
function, molecular transport, cellular assembly, organization and function, as well as cell and tissue morphology 
were on the top down-regulated functions by HF/DDE. Top transcription factors associated with HF/DDE (see 
Supplementary Fig. S1) disclosed an activation of hepatocyte nuclear factor 4 alpha (HNF4A; z-score 2.427) and 
a contrary trend for estrogen receptor alpha (Esr1). Simulating a data network between transcription factors and 
modulated genes using IPA, we observed a link between the transcription factors Esr1 and Isl1, and Gal.
Effects of all treatments in expression of specific genes and treatment-dependent changes 
in Galanin promoter methylation status. Nervous system development and function-related 
genes were evaluated by qRT-PCR (Fig. 6). We observed an overall up-regulation of selected genes, namely 
Figure 5. Mesenteric visceral adipose tissue morphology and proliferative and apoptotic status. (A) adipocyte 
area; (B) adipocyte distribution regarding their size; (C) proliferation; (D) apoptosis; (E) proliferation/apoptosis 
ratio. Statistical analysis with two-way ANOVA (main effects: diet, p,p’-DDE exposure and their interaction; 
p < 0.05), followed by Tukey’s multiple comparison post-hoc test: *p < 0.05 vs St; #p < 0.05 vs HF. Scale bar 
represents 200 μm. St, standard diet; HF, high fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene.
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neuropeptide-related genes Gal, Npy, Nmu and Sst and the galanin receptor 1 (Galr1), in HF group compar-
ing to other treatments, including HF/DDE (significant interaction between HF diet and p,p’-DDE; exposure). 
Several neuroreceptor transcripts such as Chrna3, Chrm2 (cholinergic receptor, muscarinic 2), and Htr3a 
(5-hydroxytryptamine receptor 3A), as well as calcium (calbindin 2; Calb2), nitric oxide (nitric oxide synthase 
1, neuronal; Nos1) and vesicle trafficking-related genes followed the same pattern. In contrast, the concomi-
tant exposure to HF diet and p,p’-DDE was associated with the up-regulation of Dpp4, Isl1 and Nampt (nico-
tinamide phosphoribosyltransferase), this last with a p,p’-DDE-dependent increase. Esr1 transcription did not 
show any difference between groups. From the nine genes with altered expression in HF/DDE animals that were 
selected for Sequenom analysis, only Gal (Fig. 7) showed changes in DNA methylation at its promoter region (see 
Supplementary Fig. S2). The HF animals (i.e. those with higher levels of expression) presented lower methylation 
of these CpGs comparing to HF/DDE and whilst the differences were small in magnitude and limited to a few 
CpGs sites, they were located near to AP-1 binding sites.
Discussion
The HF-fed rats exhibited several of the MetS features (Fig. 8) already described for this model43, 44, namely: a 
rapid weight gain, mostly due to a dramatic increase in AT mass; dysglycaemia with impaired response to glucose 
and tendentiously higher fasting insulin levels and HOMA index, mild dyslipidaemia; hyperleptinemia; and a 
reduction of the anti-inflammatory cytokine IL-10, alongside with a slight decrease in TGF-β1 levels, an immune 
system-modulating cytokine45.
However, our fundamental focus was on the assessment of p,p’-DDE exposure when supplied in an obe-
sogenic context. Our study has revealed that HF-fed rats exposed to p,p’-DDE develop a severe and more exuber-
ant metabolic dysfunction, independent of body weight changes (Fig. 8). The interaction between HF diet and 
p,p’-DDE exposure observed in this study corroborates the suggestion that contaminants in foods can contribute 
to the worsening of metabolic complications of obesity25, and allowed us to further explore their causal effects.
Accordingly, HF/DDE had a clear aggravation of glycaemic metabolism (Fig. 3A), with a significant effect of 
p,p’-DDE increasing fasting blood glucose levels and impairing glycaemia control with a pronounced tendency of 
increased fasting insulin levels and HOMA index for insulin resistance, effects to some extent already observed in 
St/DDE and in accordance with studies linking p,p’-DDE exposure to insulin resistance and T2D8, 29, 40–42.
In this context, the up-regulation of Dpp4 transcription in HF/DDE mesenteric vAT (see Supplementary 
Table S2 and Fig. 6) could be contributing for their metabolic impairment worsening, as recently described46, 47. 
In fact, Dpp4 (also known as CD26) is a ubiquitously expressed glycoprotein that is responsible for the rapid 
Top overall Bio functions and pathways Ranking of functions (down and up-regulated genes analysed in separate)
Molecular and Cellular Functions p value # genes Down-regulated genes p value Up-regulated genes p value
Cell-to-cell Signalling and 
interaction 1.93 × 10
−12 75 Cell-to-cell Signalling and interaction 1.96 × 10
−25 Tissue Morphology 2.04 × 10−4
Molecular transport 5.67 × 10−10 68 Nervous System Development and Function 1.21 × 10
−18 DNA Replication, Recombination, 
and Repair 2.68 × 10
−4
Small molecule biochemistry 5.67 × 10−10 75 Genetic Disorder 1.62 × 10−17 Cellular Assembly and Organization 4.71 × 10
−4
Cell morphology 5.40 × 10−07 56 Neurological Disease 1.62 × 10−17 Cellular Function and Maintenance 4.71 × 10−4
Cellular assembly and organization 5.40 × 10−07 95 Psychological Disorders 1.62 × 10−17 Cellular Development 6.62 × 10−4
Physiological system development 
and function p value # genes Behaviour 1.65 × 10
−12 Embryonic Development 6.62 × 10−4
Nervous system development and 
function 1.93 × 10
−12 114 Skeletal and Muscular Disorders 7.28 × 10−12 Gene Expression 7.71 × 10−4
Behaviour 2.26 × 10−07 59 Molecular Transport 9.57 × 10−10 Cancer 1.31 × 10−3
Tissue development 4.06 × 10−06 56 Small Molecule Biochemistry 9.57 × 10−10 Cell Death 1.31 × 10−3
Skeletal and muscular system 
development and function 7.61 × 10
−06 25 Cellular Assembly and Organization 1.72 × 10
−9 Reproductive System Disease 1.31 × 10−3
Tissue morphology 7.61 × 10−06 56 Cellular Function and Maintenance 1.72 × 10
−9 Cell Morphology 1.39 × 10−3
Canonical pathways p value Ratio Nutritional Disease 9.01 × 10−8 Nervous System Development and Function 2.80 × 10
−3
Serotonin receptor signalling 5.77 × 10−03 4/46 (0.087) Skeletal and Muscular System Development and Function 1.03 × 10
−7 Cardiovascular System 
Development and Function 3.80 × 10
−3
Xenobiotic metabolism signalling 2.73 × 10−02 12/294 (0.041) Tissue Morphology 1.03 × 10−7 Protein Synthesis 5.38 × 10−3
LPS/IL-1 mediated inhibition of 
RXR function 3.18 × 10
−02 10/235 (0.043) Cell Morphology 2.63 × 10−7 Cellular Growth and Proliferation 6.00 × 10−3
Pentose phosphate pathway 3.60 × 10−02 3/80 (0.038) Organismal Injury and Abnormalities 2.66 × 10
−7 Auditory and Vestibular System 
Development and Function 6.15 × 10
−3
cAMP-mediated signalling 3.80 × 10−02 10/219 (0.046) Cellular Development 2.70 × 10−7 Behaviour 6.15 × 10−3
Table 1. Ingenuity pathway analysis of HF/DDE regulated genes, either evaluating the overall differentially 
transcribed genes or with down and up-regulated genes analysed in separate. The ratio refers to the proportion 
of molecules within the pathway.
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catalytic degradation of incretins, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide 
(GIP), responsibles for an important part of postprandial insulin secretion. DPP4 also mediates the degradation 
of many growth factors and hormones, chemokines and neuropeptides and is up regulated in pro-inflammatory 
states including obesity and T2D48, 49. Recently, Dpp4 was also considered a novel cross-talk adipokine with auto-
crine and paracrine effects on insulin sensitivity impairment48, 50. On the other hand, insulin resistance may play 
an important role in the development of hypertension51. Corroborating epidemiological data27, 52, p,p’-DDE man-
ifestly induced hypertension (Fig. 3B), an effect that was aggravated by the simultaneous ingestion of HF diet, but 
apparently distinct from those induced by HF diet alone.
Furthermore, one cannot overlook the probable effects of dyslipidaemia observed in HF/DDE animals 
(Fig. 3C), which, through lipotoxic events in insulin-responsive organs, may contribute to a reduction in periph-
eral insulin response. Indeed, p,p’-DDE exposure contributed to a more marked dyslipidaemia compared to HF 
diet alone, namely with higher HDL levels, the main transporter of cholesterol in rats. Additionally, without an 
overall increase in HF-fed rats NEFAs53, HF/DDE vAT lipolysis was increased (Fig. 2B), although in a smaller 
Figure 6. Gene expression analysis by quantitative real-time PCR (qRT-PCR) in visceral adipose tissue. Gene 
expression normalised to the housekeeping genes (Hprt, Gusb and Tbp). Statistical analysis with two-way 
ANOVA (main effects: diet, p,p’-DDE exposure and their interaction; p < 0.05), followed by Tukey’s multiple 
comparison post-hoc test: *p < 0.05 vs St, #p < 0.05 vs HF/DDE and Øp < 0.05 vs St/DDE. St, standard diet; HF, 
high fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene.
www.nature.com/scientificreports/
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magnitude compared to St/DDE animals, probably due to an overwhelming effect of HF or a different p,p’-DDE 
concentration profile.
Taking into account an adipocentric view of metabolic dysfunction, we further evaluated the contribution of 
the mesenteric vAT impairment, considered determinant in the causal pathway of the MetS and dysmetabolic 
obesity3, 4. The AT inability to accommodate more lipids leads to functional and morphological changes, AT 
remodeling, in order to achieve a new equilibrium39. However, the apparent remodeling dynamics observed in 
HF group, characterized by higher proliferation and apoptotic indexes, was impaired by the interaction with 
p,p’-DDE exposure, patent in decreased proliferation and lesser percentage of bigger adipocytes, without an effect 
on mean adipocyte area (Fig. 5). Indeed, an expanded population of small and dysfunctional adipocytes, charac-
terized by lower differentiation capacity and impaired capacity to control endocrine homeostasis, and therefore 
energy, metabolic and inflammatory homeostasis24, 54, 55, may contribute to obesity-associated insulin resistance56.
To further explore the underlying molecular mechanisms, we conducted a global gene expression evaluation 
between HF and HF/DDE, revealing a down-regulation of nervous system development and function-related 
genes, as well as of tissue development, signalling and metabolism-related genes (see Supplementary Table S2 
and Table 1). To comprehend the importance of differences between HF groups, several genes of interest were 
Figure 7. Methylation profile of galanin (Gal) promoter region in mesenteric vAT measured by Sequenom 
MassARRAY. The results are presented as average of percentage methylation ± SEM for each CpG site or 
aggregate of CpG sites. Statistical analysis unpaired t test: #p < 0.05. Gray area represents a CpG island. HF, high 
fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene; TSS, transcription start site.
Figure 8. Schematic representation of the effects observed with the different treatments, whereby p,p’-DDE 
exposure appears to have an effect in metabolic syndrome evolution and dysmetabolic obesity, namely by 
exacerbating the effects of HF, in which the impairment of AT normal function seems to play a central role. St, 
standard diet; HF, high fat diet; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene; vAT, visceral adipose tissue.
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evaluated in all treatments (Fig. 6). The higher expression of nervous system-related genes in HF rats compared 
to a non-obesogenic context, possibly in response to higher energy influx and AT increase as is known that high 
caloric intake leads to an increased sympathetic tone57, seem impaired when rats were also exposed to p,p’-DDE, 
possibly contributing to AT dysfunction. Indeed, the autonomic innervation of AT is important in the regula-
tion of tissue mass and function through neuro-adipose junctions that also mediate leptin-driven lipolysis58, 59. 
Moreover, exposure to EDCs, namely p,p’-DDE, have been associated with several effects on the nervous system, 
acting not only as neurotoxicants but also disrupting neurotransmitter function60, 61.
These changes are demonstrative of the decrease in competent metabolic control cross-talk mechanisms, as 
AT is known to be innervated by the autonomic nervous system, especially by sympathetic nerves62. Moreover, 
parasympathetic innervation in AT, along with the ability of macrophages to participate in this cross-talk63, has 
been recently linked with cytokine production, inflammation, energy homeostasis and insulin resistance trough 
the cholinergic anti-inflammatory pathway64. Remarkably, several genes related to parasympathetic nervous sys-
tem, such as cholinergic receptors and Nos1, were down-regulated.
Additionally, transcript levels of some neuropeptides followed the same pattern. Gal, the most altered gene 
(receptor also down-regulated), is involved in the positive regulation of food intake and the risk for obesity, but 
also contributes to the decrease of insulin resistance and blood pressure65, 66. Gal is engaged in the regulation of 
numerous physiological processes and distributed widely throughout the central and peripheral nervous system 
and other tissues, such as vAT. The mechanisms underlying the effects of Gal on appetite and obesity are its 
interaction with other appetite-regulating peptides, such as the positive interaction with Npy and negative with 
leptin, and the stimulation of muscle to use carbohydrates over lipids67. Indeed, as in vivo evidence suggest, Gal 
may counteract the metabolic disturbances induced by a HF diet, in part corroborated in this study, by means of 
the favouring of carbohydrate over lipid metabolism in muscle67, 68.
One can also hypothesize about the possible molecular mechanism involved in this HF diet x p,p’-DDE expo-
sure interaction. As xenoestrogen, p,p’-DDE can interfere with estrogen signalling, namely in the induction of 
Gal69. The considerable inhibition of Esr1 transcription factor status in HF/DDE animals (see Supplementary 
Fig. S1), notwithstanding its unaltered transcription (Fig. 6), can be related with the Isl1-ER cross-talk ability to 
inhibit the ER-driven transcriptional activation70. Alternatively, compared to HF/DDE, the HF animals presented 
a decrease in DNA methylation at Gal regulatory region near to AP-1 binding sites, which could also help explain 
its increased expression (Fig. 7). Once more, p,p’-DDE exposure demonstrated to counteract this effect.
Furthermore, the HF diet x p,p’-DDE exposure interaction led to an increase of inflammation (Fig. 4), with 
a striking increase in plasmatic IL-1β levels, to some extent also seen in St/DDE group, alongside a decline in 
anti-inflammatory cytokines. This cytokine, is implicated in T2D through the activation of the inflammasome, 
and important part of our innate immune system that responds to danger signals that are sensed by intracellular 
NOD-like receptors (NLRs), such as NLRP3 inflammasome that after activation facilitates caspase-1-dependent 
processing of pro-IL-1β into its active form71. Indeed, IL-1β is associated with visceral obesity and β cell failure72, 
73, promotion of AT inflammation and limitation of fat expandability, ultimately contributing to ectopic lipid 
accumulation and disturbed fat-liver crosstalk71, 73, 74, as well as to cardiac arrhythmias75. In this regard, a negative 
correlation was observed between the weight of vAT and other metabolically active organs susceptible to accumu-
late lipids, especially liver (data not shown). Moreover, we already described that p,p’-DDE exposure associated 
with HF diet enhances the impairment of liver fatty acid composition and increases their overall levels, confirm-
ing a close relationship with hepatic lipid dysfunction76. Despite its well accepted relation with dysmetabolic 
obesity, the triggers that determine differential inflammasome activation remain to be identified73, emerging the 
environmental exposure to POPs, and EDCs in general, as another plausible mechanism.
This AT impairment contributes to the dysfunction of other metabolically active organs and interfere with its 
toxicological functions, namely of protection13. Indeed, HF/DDE animals presented a strong indication of cellular 
damage, with a significant increase of AST, AST/ALT and CK only in HF diet-fed animals exposed to p,p’-DDE, 
which may imply liver, kidney or muscle damage (see Supplementary Table S1). Ultimately, this damage can have 
a plausible relationship with the observed metabolic dysfunction, namely with glucose intolerance as a result of 
pancreas damage, expressed by an increase in total plasmatic amylase. Moreover, the observed renal dysfunction 
could also implicate this organ in the MetS aggravation by p,p’-DDE exposure77, expressed in higher glucose and 
urea excretion in HF/DDE animals, alongside with a dramatic increase of microalbuminuria. One can also spec-
ulate on the involvement of oxidative stress and hyperuricaemia, as well as the increase in lactate levels, on the 
development of insulin resistance and MetS78.
Taken together, our results confirm that p,p’-DDE exposure appears to have an important effect in MetS evo-
lution and dysmetabolic obesity, exacerbating the effects of HF diet, in which the impairment of AT normal 
function seems to play an important role (Fig. 8). We verified that although p,p’-DDE exposure did not led to 
increased obesity, it contributed to a more exuberant MetS, aggravating some of its features, such as glucose intol-
erance, hypertension, dyslipidaemia and inflammation. In an adipocentric view of the genesis of MetS, the results 
of the mesenteric vAT evaluation also point to a deleterious effect of exposure to p,p’-DDE in a HF diet context. 
In addition, p,p’-DDE also exerts noteworthy independent effects, as the induction of hypertension, elevated 
fasting glucose and inflammation, even when not in an obesogenic context. The involvement of p,p’-DDE in these 
pathological developments emphasizes the need for a better understanding of EDCs mechanisms of action and 
their recognition as metabolism disrupting chemicals. To some extent, these results can help explain the interin-
dividual variability of obesity effects and introduce these compounds as possible markers of dysmetabolic obesity.
Methods
Animal treatment. Twenty-four male Wistar rats, weighing 267 ± 11.8 g (8 weeks), were purchased from 
Charles River (Barcelona, Spain) and after at least 1 week of acclimatization under controlled environmental 
conditions (22–24 °C and 12 h light/dark cycles), were randomly divided into four groups and treated for 12 
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weeks: St, standard diet group; St/DDE, standard diet with p,p’-DDE exposed group; HF, high-fat diet group; HF/
DDE, high-fat diet with p,p’-DDE exposed group. The p,p’-DDE exposure was applied in drinking water with the 
average concentration of 100 μg/kg/day (2.5 times less than lowest-observed-adverse-effect level). The “Standard” 
(Teklad 2014, Harlan Laboratories, Santiga, Spain) and “High Fat” (D1245 Research Diets, New Brunswick, 
USA) diets had, respectively, 13% and 45% of energy from lipids. Body weights were monitored weekly. For the 
extended treatment details see Supplementary Methods online. Animal handling and housing protocols followed 
European Union guidelines (Directive 2010/63/EU) and Portuguese Act (129/92) for the use of experimental 
animals. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Faculty of 
Medicine of University of Porto.
Evaluation of metabolic parameters. Oral glucose tolerance test (OGTT). After 7 weeks of treatment, 
the rats were fasted for 4–6 hours and a baseline blood drawn from the saphenous vein was collected for plasma 
fasting glucose evaluation79. The rats were gavaged with a glucose solution (2 mg/g of body weight) and glycae-
mia measured thereafter until 120 min. Glucose levels were measured with Precision Xtra Plus test strips using a 
Optium Xceed device (Abbott Diabetes Care, Ltd., Maidenhead, UK). Plasma insulin levels at the end of the study 
were measured using a Rat/Mouse Insulin ELISA kit (Merck Milipore, Madrid, Spain). The homeostasis model 
assessment (HOMA) was used to calculate approximate insulin resistance using the formula: glucose (mg/dL) x 
insulin (ng/ml)/40580.
Systolic blood pressure evaluation. Measurement of SBP in conscious restrained rats was carried out by the non-
invasive tail-cuff method81 using LE 5000 (Letica, Rochester Hills, USA) at weeks 4, 7 and 10. Each value of SBP 
was obtained by averaging out three to five consecutive similar measurements.
Blood and urine biochemical analysis. Biochemical evaluation of plasma and urine was performed at São João 
Hospital Center Clinical Pathology Department. Routine biochemical parameters were measured using conven-
tional methods with an Olympus AU5400® automated clinical chemistry analyser (Beckman-Coulter®, Izasa, 
Porto, Portugal). Low-density lipoprotein (LDL) cholesterol was calculated according to Friedewald’s equation82. 
NEFAs were quantified using an in vitro enzymatic colorimetric method assay (Wako Chemicals GmbH, Neuss, 
Germany).
Cytokine profile evaluation. Interleukin-1 beta (IL-1β), IL-10), tumor necrosis factor-alpha (TNF-α) and trans-
forming growth factor-beta 1 (TGF-β1) were measured with custom Milliplex Rat kits (Merck Millipore, Madrid, 
Spain), using Luminex xMAP Multiplexing Technology platform. Leptin, adiponectin and monocyte chemoat-
tractant protein-1 (MCP-1) were determined using, respectively, Rat Leptin ELISA Kit (Merck Millipore, Madrid, 
Spain), Adiponectin Enzyme Immunoassay Kit and MCP-1 ELISA Kit (RayBiotech, Norcross, USA).
Adipocyte isolation, lipolysis and determination of p,p’-DDE in the AT. Portions of visceral and 
subcutaneous AT (epididymal vAT and scAT, respectively) were used for adipocyte isolation according to the 
method of Rodbell et al.83 with some modifications, and determination of lipolysis (see Supplementary Methods 
online). The p,p’-DDE analysis was performed according to the method described by Fernandes & Pestana et al.84, 
and were expressed as µg of p,p’-DDE/kg of tissue or as p,p’-DDE burden in AT.
AT morphology, apoptosis and proliferation. A portion of mesenteric vAT was fixed in buffered for-
maldehyde 10%, at least for 48 h (4 °C), dehydrated and finally embedded in paraffin. Three µm thick sections were 
obtained with a Leica® Microtome (RM2125RT, Lisbon, Portugal) for morphological analysis, apoptosis deter-
mination, and immunohistochemistry. Adipocyte size measurement was performed from hematoxylin-eosin–
stained tissue sections as previously described27. Apoptosis was analysed using the terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end-labeling (Roche) and proliferation the immuno-
histochemical labeling of protein Ki67 protein85 (anti-Ki67, 1:50; fluorescein isothiocyanate-conjugated sec-
ondary antibody, 1:200; in 4% bovine serum albumin; Santa Cruz Biotechnology), with simultaneous of total 
DAPI-stained nuclei (4′,6-diamidine-2′-phenylindole dihydrochloride; Roche) count for the same optical fields. 
Apoptosis and proliferation were determined as the percentage of positive cells over total counted cells. Images 
from five randomly-selected different optical fields were acquired, under specimen identity occultation, with 
a Nikon Eclipse 50i® microscope and analysed with ImageJ software® (National Institute of Health, Bethesda, 
USA).
AT total RNA isolation and microarrays. Total RNA was isolated from mesenteric vAT samples ground 
in liquid nitrogen, using RNA STAT-60 reagent (AMS Biotechnology, Abingdon, UK) followed by chloroform 
extraction and isopropanol precipitation. RNA extracts were treated with DNaseI to avoid contamination with 
genomic DNA and its concentration was assessed spectrophotometrically with a NanoDrop spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA), and their integrity determined with the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Massy, France). Only the high-quality RNA was processed and samples from HF and HF/
DDE rats were used for the microarray analysis. Sample processing and data acquisition were carried out by the 
Genomics Core Lab of the University of Cambridge Biomedical Research Centre (Cambridge, UK). Biotinylated 
cRNA preparation and hybridization to Affymetrix Rat GeneChip® Gene 1.0 ST Arrays were performed accord-
ing to the recommended Affymetrix protocol (GeneChip Expression Analysis Technical Manual, Affymetrix, 
Santa Clara, CA, USA). Arrays were scanned and raw image data were converted to CEL files using Affymetrix 
Genechip Software.
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Microarray data analysis and functional profiling. All downstream analysis of microarray data was 
performed using Agilent’s GeneSpring GX 9 software (Agilent Technologies Inc. Santa Clara, USA). After import-
ing the data, the CEL files were analysed under high stringency in order to reduce the number of false positives, as 
previously reported86. Two different analysis algorithms were used (robust multi-array average (RMA) and Plier 
analysis) and only genes whose expression patterns in each of the analyses were identical were taken forward for 
further study. Gene expression levels were considered significantly up- or down-regulated with a fold change of at 
least 1.25 fold with a p value of 5% (Student’s t-test). The pathway and biological analysis of gene expression data 
was performed using the Ingenuity pathway analysis software (IPA, Ingenuity® Systems, Redwood City, USA).
Gene expression analysis by quantitative real-time PCR (qRT-PCR). To validate the microarray 
data, 10 differentially transcribed genes (up- and down-regulated) were selected for qRT-PCR analysis (see 
Supplementary Fig. S3). Several target genes’ expression levels were evaluated in all treatment groups. Total 
RNA (1 μg) was reverse transcribed to cDNA using Multiscribe Reverse Transcriptase with random primers 
according to the manufacturer’s protocol (Applied Biosystems). All cDNA samples were analysed in triplicate 
by qRT-PCRs conducted with SYBR green qPCR Mix (SYBR Green JumpStart Taq ReadyMix for qPCR, Sigma) 
on a 7500 Fast Real-Time PCR System (Applied Biosystems, UK). Gene expression was calculated using the 
2−ΔCT method87 and normalized against the geometric mean expression levels of the endogenous control genes: 
hypoxanthine-guanine-phosphoribosyltransferase (Hprt), β-glucuronidase (Gusb) and TATA box binding pro-
tein (Tbp). Gene-specific primers are listed in Supplementary Table S3.
Sequenom MassARRAY quantitative methylation analysis. Genomic DNA was isolated from 
mesenteric vAT following standard methods and methylation analysis was performed following the protocol 
recommended by Sequenom (Sequenom, San Diego, USA). Aliquots of 0.5 μg were converted with sodium 
bisulphite using the EZ DNA Methylation™ Kit according to the manufacturer’s instructions (Zymo Research, 
Irvine, USA). Amplification of bisulphite-treated DNA (~2.5 ng μl−1) was performed using HotStarTaq DNA pol-
ymerase (Qiagen, UK) and primer pairs designed with Sequenom EpiDesigner (see parameters summarized in 
Supplementary Table S4). The PCR programme consisted of an initial 15 min denaturation at 94 °C followed by 45 
cycles of 20 s at 94 °C, 30 s at the annealing temperature and 1 min at 72 °C. According to the manufacturer’s pro-
tocol (Sequenom Inc., CA, USA), the amplicons of bisulfite PCR were treated with shrimp alkaline phosphatase 
(SAP) followed by in vitro transcription with T7 RNA polymerase and base-specific cleavage using MassCLEAVE 
T cleavage kit. The samples were desalted and spotted on a 384-SpectroCHIP (Sequenom), followed by spectral 
acquisition on a MassARRAY Analyzer Compact MALDI-TOF MS (Sequenom). The resulting methylation calls 
were performed by the EpiTYPER software (Sequenom) to generate quantitative results for each CpG site or an 
aggregate of CpG sites. Three independent bisulphite-converted DNAs were analysed per sample. Quantification 
of methylation was performed in triplicate and the average of the two most concordant replicates was taken 
at each CpG site. The average methylation was calculated as a mean value of the CpG methylation values and 
expressed as percentage methylation.
Statistical analysis. Values are expressed as the arithmetic mean ± standard error of the mean (SEM). 
Two-way ANOVA was used to determine the main effects of diet [Standard (St and St/DDE) vs High-fat diet 
(HF and HF/DDE)], p,p’-DDE exposure [non-exposed (St and HF) vs exposed Rats (St/DDE and HF/DDE)] and 
their interaction (diet x p,p’-DDE exposure). Posteriorly, tukey’s multiple comparison post-hoc test was used to 
determine differences between all experimental groups and represented with corresponding symbols. Two-way 
ANOVA repeated measures followed by Tukey’s multiple comparison post-hoc test was used to evaluate the 
differences between experimental conditions throughout time. To analyse the differences between 2 groups, a 
Student’s t test was used: unpaired t test when comparing methylation profile between treatment groups (HF 
and HF/DDE); regarding p,p’-DDE concentrations and p,p’-DDE burden in AT, unpaired t test when comparing 
between treatment groups (St/DDE and HF/DDE) and paired t test when comparing between different ATs from 
the same treatment group. The association between various parameters were analysed computing Pearson’s corre-
lation coefficients. All statistical analyses were performed using GraphPad Prism 6 statistical software (GraphPad 
Software Inc., La Jolla, USA). The differences were considered statistically significant when p < 0.05.
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